Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 7, 2016

Actelion reports positive Merit study results of macitentan to treat pulmonary hypertension

Swiss bio-technology company Actelion has reported positive results from its macitentan in the treatment of Inoperable chronic thromboembolic pulmonary hypertension (Merit) study of macitentan in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension.

Swiss bio-technology company Actelion has reported positive results from its macitentan in the treatment of Inoperable chronic thromboembolic pulmonary hypertension (Merit) study of macitentan in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension.

The Merit study has been conducted as a Phase II prospective, randomised, placebo-controlled, double-blind, multi-centre, parallel-group trial intended to examine the efficacy, safety and tolerability of macitentan.

The study included 80 inoperable patients who were randomised to be administered with 10mg of macitentan and placebo for a period of 24 weeks.

Results suggested that macitentan exhibited a positive impact on exercise capacity of the patients compared to placebo, with a 16% reduction in pulmonary vascular resistance (PVR) observed in the macitentan treatment group.

"The company will now fully analyse the data and discuss the findings with health authorities."

The study also suggsted the safety and tolerability of macitentan consistent with the previous clinical studies. 

Actelion global clinical development head Guy Braunstein said: “Inoperable chronic thromboembolic pulmonary hypertension is associated with a poor prognosis if left untreated, and additional therapeutic options are needed for these patients who are not candidates for surgery. 

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

"I am very pleased that the study has shown a significant decrease in PVR with macitentan and by the significant improvement in exercise capacity. I would like to thank everyone who has participated in this study.

"The company will now fully analyse the data and discuss the findings with health authorities.”

Actelion has developed macitentan as an orally administered endothelin receptor antagonist.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU